Dr. Marc Pliskin of The Urology Group talks about a groundbreaking treatment for late-stage prostate cancer called Lutetium-177 PSMA, that was just approved last week by the FDA. It is radioactive therapy that finds the cancer cells wherever they are in the body. The goal of this treatment is to prolong a better quality of life for those with metastatic prostate cancer.
